AnaptysBio (NASDAQ:ANAB) Earns Outperform Rating from Analysts at Wolfe Research

Wolfe Research began coverage on shares of AnaptysBio (NASDAQ:ANAB) in a report published on Tuesday, Marketbeat.com reports. The brokerage issued an outperform rating and a $25.00 target price on the biotechnology company’s stock.

A number of other research analysts also recently commented on the company. Wells Fargo & Company lowered their target price on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. UBS Group increased their price objective on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Truist Financial reduced their target price on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Finally, JPMorgan Chase & Co. dropped their price target on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $40.08.

AnaptysBio Price Performance

NASDAQ:ANAB opened at $16.08 on Tuesday. The stock has a market cap of $489.30 million and a PE ratio of -2.64. AnaptysBio has a fifty-two week low of $12.51 and a fifty-two week high of $41.31. The stock’s 50-day moving average is $16.87 and its two-hundred day moving average is $26.69.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. On average, equities research analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current year.

Insider Transactions at AnaptysBio

In related news, Director Ecor1 Capital, Llc acquired 65,184 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were bought at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the acquisition, the director now owns 7,860,180 shares in the company, valued at $101,553,525.60. This trade represents a 0.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 33.70% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Institutional investors have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. raised its holdings in AnaptysBio by 2.0% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after acquiring an additional 43,598 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of AnaptysBio by 202.8% during the third quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock valued at $1,816,000 after purchasing an additional 36,300 shares during the period. JPMorgan Chase & Co. raised its stake in shares of AnaptysBio by 191.4% in the third quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company’s stock valued at $1,130,000 after purchasing an additional 22,164 shares in the last quarter. Victory Capital Management Inc. lifted its position in AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after purchasing an additional 206,750 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after buying an additional 168,813 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.